Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
0.113 EUR | -9.96% |
|
-36.67% | -89.54% |
Jun. 28 | GeNeuro: failure of phase 2 study in Covid long | CF |
Jun. 28 | GeNeuro Announces Results of the Gnc-501 Study in Post-Covid-19 Syndrome | CI |
- Stock Market
- Equities
- GNRO Stock
- News GeNeuro SA
- Highlights